argenx
argenx.comTotal trials
79
Active
38
Phase 3
31
Total enrollment
9,106
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 15 of 15 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Efgartigimod PH20 SC | — | 23 | |||||
| Efgartigimod IV | — | — | 12 | ||||
| Empasiprubart IV | — | — | 6 | ||||
| Empasiprubart | — | — | — | — | — | 2 | |
| IVIG | — | — | — | — | — | 2 | |
| EFG PH20 SC | — | — | — | — | — | 1 | |
| Efgartigimod IV or Efgartigimod PH20 SC | — | — | — | — | — | 1 | |
| ARGX-117 | — | — | — | — | 4 | ||
| ARGX-119 | — | — | — | — | 3 | ||
| ARGX-119 IV | — | — | — | — | — | 1 | |
| Efgartigimod PH20 SC - prefilled syringe | — | — | — | — | — | 1 | |
| Efgartigimod PH20 (ARGX-113) SC | — | — | — | — | — | 1 | |
| empasiprubart SC AI | — | — | — | — | — | 1 | |
| ARGX-124 | — | — | — | — | — | 1 | |
| Efgartigimod | — | — | 10 |
Next readouts
- 2025-06-30
- 2025-10-16
- 2026-01
- 2026-08
- 2026-08
- 2026-09
- 2026-09-30
- 2026-10-01
- 2026-11
- 2026-12-01
Top conditions
- Generalized Myasthenia Gravis11
- Healthy Volunteers9
- Myasthenia Gravis6
- gMG6
- Primary Immune Thrombocytopenia5
- CIDP4
- Myositis3
- Dermatomyositis3
Frequently asked questions about argenx
- How many clinical trials does argenx have on ClinicalTrials.gov?
- argenx is listed as the lead sponsor on 79 clinical trials in ClinicalTrials.gov, 38 of which are currently active (recruiting, enrolling, or ongoing).
- How many of argenx's trials are in Phase 3?
- 31 of argenx's trials are in Phase 3, spread across 15 active drug programs.
- What therapeutic areas does argenx focus on?
- argenx's most-studied conditions on ClinicalTrials.gov are Generalized Myasthenia Gravis, Healthy Volunteers, Myasthenia Gravis, gMG, Primary Immune Thrombocytopenia.
- When are argenx's next clinical trial readouts?
- argenx has 10 upcoming primary-completion readouts tracked here; the soonest is “A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis”, expected around 2025-06-30.